• Explore /
  • Poster
  • / Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.

Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.

Abstract Video & Slides Poster

Authors

null

Jaime R. Merchan

University of Miami, Miami, FL

Jaime R. Merchan , Manish Patel , Timothy P. Cripe , Matthew O. Old , James Fredric Strauss , Amber Thomassen , Rosa M Diaz , Kah Whye Peng , Stephen J. Russell , Luke Russell , Monica Reckner , Erol Wiegert , Alice Susannah Bexon , Steven Francis Powell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT02923466

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3090)

DOI

10.1200/JCO.2020.38.15_suppl.3090

Abstract #

3090

Poster Bd #

154

Abstract Disclosures

Similar Posters

First Author: Yiqun Du

First Author: Dan Liu

First Author: Jifang Gong

First Author: Abhishek Tripathi